Correction to: Mitochondrial H+-ATP synthase in human skeletal muscle: contribution to dyslipidaemia and insulin resistance

Correction to: Mitochondrial H⁺-ATP synthase in human skeletal muscle: contribution to dyslipidaemia and insulin resistance

Diabetologia. 2018 Dec;61(12):2674. doi: 10.1007/s00125-018-4747-3.

Laura Formentini^{1

2

3}, Alexander J Ryan^{4

5

6}, Manuel Gálvez-Santisteban⁵, Leslie Carter⁴, Pam Taub^{4

7}, John D Lapek Jr⁸, David J Gonzalez⁸, Francisco Villarreal⁵, Theodore P Ciaraldi^{4

5}, José M Cuezva⁹, Robert R Henry^{4

5}

¹ VA San Diego Healthcare System, San Diego, CA, USA. lformentini@cbm.csic.es.
² Departamento de Biología Molecular, CIBER Enfermedades Raras, Centro de Biología Molecular 'Severo Ochoa' (CBMSO), c/ Nicolás Cabrera 1, Universidad Autónoma de Madrid, 28049, Madrid, Spain. lformentini@cbm.csic.es.
³ Department of Medicine, University of California, San Diego, La Jolla, CA, USA. lformentini@cbm.csic.es.
⁴ VA San Diego Healthcare System, San Diego, CA, USA.
⁵ Department of Medicine, University of California, San Diego, La Jolla, CA, USA.
⁶ Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
⁷ Department of Cardiology, University of California, San Diego, La Jolla, CA, USA.
⁸ Department of Pharmacology and Pharmacy, University of California, San Diego, La Jolla, CA, USA.
⁹ Departamento de Biología Molecular, CIBER Enfermedades Raras, Centro de Biología Molecular 'Severo Ochoa' (CBMSO), c/ Nicolás Cabrera 1, Universidad Autónoma de Madrid, 28049, Madrid, Spain.

Owing to an oversight, the authors omitted to note that Dr Taub is a co-founder of and equity holder in Cardero Therapeutics.